Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?

Julien Lazarovici; Marie Terroir-Cassou-Mounat; David Ghez

首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?

【24h】

Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?

机译：回复：临时FDG-PET / CT在原发性纵隔弥漫性大B细胞淋巴瘤：真的几乎没用的程序？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Nuclear Medicine and Molecular Imaging》 |2018年第5期|共2页
作者
Julien Lazarovici; Marie Terroir-Cassou-Mounat; David Ghez;
展开▼
作者单位

Department of Hematology Gustave Roussy and Université Paris Saclay;

Department of Nuclear Medicine and Endocrine Oncology Gustave Roussy and Université Paris Saclay;

Department of Hematology Gustave Roussy and Université Paris Saclay;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
入库时间 2022-08-20 02:47:00

相似文献

外文文献
中文文献
专利

1. Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure? [J] . Julien Lazarovici, Marie Terroir-Cassou-Mounat, David Ghez European Journal of Nuclear Medicine and Molecular Imaging . 2018,第5期

机译：回复：临时FDG-PET / CT在原发性纵隔弥漫性大B细胞淋巴瘤：真的几乎没用的程序？
2. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma [J] . Lazarovici Julien, Terroir Marie, Arfi-Rouche Julia, European Journal of Nuclear Medicine and Molecular Imaging . 2017,第12期

机译：原发性纵隔大B细胞淋巴瘤正临时FDG-PET / CT的预测值差
3. Yescarta (R) (Axicabtagen Ciloleucel) receives EU Marketing Authorization for the Treatment of relapsed or refractory diffuse large B-Cell Lymphoma and primary mediastinal B-Cell Lymphoma after two or more previous systemic Therapies [J] . Oncology research and treatment. . 2018,第10期

机译：Yescarta（r）（Axicabtagen Ciloleucel）接受欧盟营销授权，用于治疗复发或难治性弥漫性大型B细胞淋巴瘤和原发性纵隔B细胞淋巴瘤后以前的两个或更多以前的全身治疗
4. Primary Breast Diffuse Large B-Cell Lymphomas [C] . Li Dan, Xie Peng, Mi Can, 5th International Conference on Bioinformatics and Biomedical Engineering . 2011

机译：原发性乳腺弥漫性大B细胞淋巴瘤
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP [O] . Kazuhiro Kitajima, Masaya Okada, Kyoko Yoshihara, 2019

机译：R-CHOP治疗弥漫性大B细胞淋巴瘤的中期FDG-PET / CT检查结果的预测价值
7. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP [O] . Kazuhiro Kitajima, Masaya Okada, Kyoko Yoshihara, 2019

机译：用R-Chec弥漫性大B细胞淋巴瘤患者临时FDG-PET / CT发现的预测值

相关主题

Reply: Interim FDG-PET/CT in primary mediastinal diffuse large B-cell lymphoma: really almost useless procedure?

著录项

相似文献

相关主题

期刊订阅